Pharmaceuticals, Biotechnology and Life Sciences
Phase 2b/3 trial of izokibep did not meet primary endpoint; secondary endpoints also did not achieve statistical significance Company continues…
TUSTIN, Calif., Dec. 10, 2024 (GLOBE NEWSWIRE) — Avid Bioservices, Inc. (NASDAQ: CDMO), a dedicated biologics contract development and manufacturing organization…
SALT LAKE CITY, Dec. 10, 2024 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and…
FOSTER CITY, Calif., Dec. 10, 2024 (GLOBE NEWSWIRE) — Apollomics Inc. (Nasdaq: APLM) (the “Company”), a clinical-stage biopharmaceutical company developing…
Interim analysis shows that tecovirimat did not improve time to lesion resolution compared to placebo in adults with mild to…
MONTREAL, Dec. 10, 2024 (GLOBE NEWSWIRE) — Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company…
WARREN, N.J., Dec. 10, 2024 (GLOBE NEWSWIRE) — Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage…
– RPT1G synergizes with venetoclax to yield an eightfold reduction in AML leukemia burden – RPT1G increases the efficacy of…
Clermont-Ferrand (France), Tuesday 10 December 2024 (6:00pm CET). CARBIOS, (Euronext Growth Paris : ALCRB), a pioneer in the development and industrialization of biological…
46% objective response rate, with 15% complete responses and 31% partial responses in patients with early-stage follicular lymphoma reported at…